A Phase I First-in-Human Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of SWA1211 Tablets in Subjects With Advanced Solid Tumors

NCT07363967 · clinicaltrials.gov ↗
PHASE1
Phase
RECRUITING
Status
60
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Beijing StoneWise Technology Co., Ltd

Collaborators